<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20190927044897N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2019-10-29</date_registration>
      <primary_sponsor>Iran University of Medical Sciences</primary_sponsor>
      <public_title>The effect of mucopexy surgical method on the incidence of postoperative complications.</public_title>
      <acronym></acronym>
      <scientific_title>Comparative study of the rate of recovery and postoperative complications of two mucopexy surgical methods with and without Doppler Guided Hemorrhoidal Artery Ligation (DG-HAL) in patients with grade 3 and 4 hemorrhoids</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2019-09-23</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>36</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/42543</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Method of randomization in this study is Simple and unit of randomization is individual. No stratified randomization is used. Sealed envelopes are used as the tool in randomization. The random sequence is built by envelopes shuffling. In allocation concealment we consider a 5-digit code for each envelope and if the third number is even the patient is in case group. If the third number is odd the patient is in control group, Blinding description: All of the participants are aware of their participation in this study and have announced their consent forms. Also, this study has the permission from ethical committee of university. the study is single-blinded, and only the participants are unaware of which of the two mucopexy surgical methods with or without DG-HAL used to treat grade 3 and 4 hemorrhoids. Also, a checklist is provided for each patient, including name, age, sex, height, weight, BMI and demographic characteristics, as well as hemorrhoid grade. These checklists with surgical procedure name coded (mucopexy with DG-HAL) as even third digit in 5-digit code and (mucopexy without DG-HAL) as odd third digit in 5-digit code randomly given to the patients before their operation.</study_design>
      <phase>2-3</phase>
      <hc_freetext>Condition 1: Grade 3 and 4 Hemorrhoids, Doppler Guided Hemorrhoidal Artery Ligation, Mucopexy with DG-HAL, Mucopexy without DG-HAL, General Surgery, Colorectal Surgery, Anorectal Diseases. Condition 2: Grade 3 and 4 Hemorrhoids, Mucopexy with DG-HAL, Mucopexy without DG-HAL, General Surgery, Colorectal Surgery, Anorectal Diseases.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: includes patients undergoing mucopexy with DG-HAL. These patients have grade 3 and 4 hemorrhoids requiring surgical intervention. DG-HAL mucopexy surgery is performed by blocking hemorrhagic artery and hemorrhoid repair using Doppler device during surgery. Intervention 2: Control group: includes patients undergoing mucopexy without DG-HAL.These patients have grade 3 and 4 hemorrhoids requiring surgical intervention. mucopexy surgery without DG-HAL is performed without the use of a Doppler device during hemorrhoid repair.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
All data can potentially be shared after making people unrecognizable.

When:
starting of accessibility will be 6 months after publication

To whom:
only available for people working in academic institutions

Conditions:
- researchers - people working in academic institutions - data could not be used in other studies. - data is available for elucidating the results of this study.

Where to obtain:
contact responsible person: dr. Sara Sohrabi, academic e-mail address: sohrabi.s@tak.iums.ac.ir , address: Firoozgar Hospital, Beh Afarin Ave., Valiasr Square, Tehran
second responsible person: dr. Mahdi AlemRajabi , Assistant professor, e-mail addres: mahdialemrajabi@gmail.com

How to obtain:
researcher information including name, address, telephone number and e-mail address - researcher CV/resume - Sending a request letter to responsible person for accessing data - Approval letter from academic institution

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Sara Sohrabi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Faculty of Medicine, Iran University of Medical Sciences, Shahid Hemmat Highway, Tehran</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1449614535</zip>
        <telephone>+98 21 8670 1021</telephone>
        <email>sohrabi.s@tak.iums.ac.ir</email>
        <affiliation>Iran University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Sara Sohrabi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Faculty of Medicine, Iran University of Medical Sciences, Shahid Hemmat Highway, Tehran</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1449614535</zip>
        <telephone>+98 21 8670 1021</telephone>
        <email>sohrabi.s@tak.iums.ac.ir</email>
        <affiliation>Iran University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Patients referred to Surgery Clinic of Firoozgar Hospital  for diagnosis of grade 3 and 4 hemorrhoids.</inclusion_criteria>
      <agemin>no limit</agemin>
      <agemax>no limit</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Patients with diagnosis of grade 1 and 2 hemorrhoids
Patients with underlying disease such as diabetes and hypertension
Patients with a history of hemorrhoidal surgery
Patients with a history of rectal surgery</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>K64</hc_code>
      <hc_code>K64.3</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Hemorrhoids and perianal venous thrombosis</hc_keyword>
      <hc_keyword>Fourth degree hemorrhoids</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Surgery</i_code>
      <i_code>Treatment - Surgery</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: includes patients undergoing mucopexy with DG-HAL. These patients have grade 3 and 4 hemorrhoids requiring surgical intervention. DG-HAL mucopexy surgery is performed by blocking hemorrhagic artery and hemorrhoid repair using Doppler device during surgery.</i_keyword>
      <i_keyword>Control group: includes patients undergoing mucopexy without DG-HAL.These patients have grade 3 and 4 hemorrhoids requiring surgical intervention. mucopexy surgery without DG-HAL is performed without the use of a Doppler device during hemorrhoid repair.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>The incidence percentage of postoperative complications of mucopexy with and without DG-HAL in patients with grade 3 and 4 hemorrhoids. Timepoint: One, three and six months after operation. Method of measurement: According to checklists and evidence of patients' history and physical examination in follow-up visits for presence or absence of pain, signs of infection, bleeding, gas incontinence, stool incontinence, anal stenosis, fistula, prolapse and hemorrhoid recurrence.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>The rate of recovery. Timepoint: One, three and six months after operation. Method of measurement: Checklists and evidence of patients' history and physical examination in follow-up visits for presence or absence of pain, signs of infection, bleeding, gas incontinence, stool incontinence, anal stenosis, fistula, prolapse, and hemorrhoid recurrence.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name>Iran University of Medical Sciences</sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Iran University of Medical Sciences</source_name>
      <source_name>Firoozgar Clinical Research Development Center(FCRDC), Firoozgar Hospital</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2019-07-23</approval_date>
        <contact_name>Ethics Committee of Iran University of Medical Sciences</contact_name>
        <contact_address>Shahid Hemmat Highway, Tehran, Tehran Province Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
